ALNY - William Blair initiates Alnylam Pharmaceuticals with outperform rating

Brokerage William Blair on Tuesday initiated an outperform rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock, while estimating a fair value for the shares of $190, which represents a 44.3% upside to the stock's last closing price of $131.63. "The company has been led by a quality management team, leverages Nobel Prize-winning science for siRNA chemistry, and has transformed into one of the most successful publicly trade rare-disease companies, in our view," wrote William Blair analysts Myles Minter and Sarah Schram. The analysts said that the primary near-term investor focus for ALNY shares is top-line data from its APOLLO-B trial evaluating its treatment Onpattro for transthyretin amyloidosis-cardiomyopathy (ATTR-CM). ATTR-CM is a potentially fatal disease which is characterized by deposits of amyloid protein fibrils in the walls of the left ventricle, which is the main pumping chamber of the heart. "We believe that Alnylam's trial conduct and supportive clinical data can rewrite BridgeBio's

For further details see:

William Blair initiates Alnylam Pharmaceuticals with outperform rating